Concepedia

Joshua A. Ballard

JA

Statistics

Publications

10

Citations

2.2K

H-Index

10

Active since

2009

Affiliations

Array BioPharma (United States)(Current)

Loxo Oncology at Lilly (United States)

Mirati Therapeutics (United States)

Dana-Farber Cancer Institute

Joshua A. Ballard is an author at Array BioPharma (United States) specializing in pharmacology, molecular oncology, and medicinal chemistry.

Publications per year

2009–2023

10

Publications

10

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.3K citations · Full text

, , +17

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Benjamin Solomon, Lavinia Tan, Stephen Q. Wong et al. · Journal of Thoracic Oncology · 2020 · 284 citations · Full text

, , +17

An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt

Kui Lin, Jie Lin, Wen‐I Wu et al. · Science Signaling · 2012 · 171 citations

, , +17

Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

Yutong Jiang, Steven W. Andrews, Kevin R. Condroski et al. · Journal of Medicinal Chemistry · 2013 · 142 citations · Full text

, , +17

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · ACS Medicinal Chemistry Letters · 2018 · 108 citations · Full text

, , +15

1–5 of 10